Align Technology stock
ALGNNASDAQAlign Technology, Inc., HealthcareISIN US0162551016
71Score 71 out of 100, Strong
Price and trend
65 / 100
Price history
+18% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 1.0% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 15% below its 52-week high. Largest decline in 20 years: 83% (September 2021 to September 2025).
Chart figures for advanced users
- SMA 50$151.50
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$168.65
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$132.28
- The lowest closing price of the last twelve months.
- Resistance$197.51
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Align Technology, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $11.77B, is number 17 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.03B (up 0.9% year on year) and earnings of $410.35M (down 2.6%).
- For fiscal 2026, analysts expect on average revenue of $4.13B (up 2.3%) and adjusted earnings per share of $11.14 (up 5.9%).
Show more
- MEQIRI Score 71 out of 100 (Strong): rank 113 of 714 in Healthcare, median 53.
- The P/E is 24.1 (Medical (Devices) median 29, own median of recent years 43.8).
- Our model puts fair value at $231.37, with the price 26% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $1.14B, financial debt $146.46M.Stability 78
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 93
- Share buybacksShare count down 8% since 2020.Capital allocation 76
Weaknesses
- Earnings per share fallingDown 24.2% a year since 2020.Growth 41
Its standout strengths are fundamentals and momentum, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 70 to 71.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $165.26 and expensive above $385.61 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $261.73 (cash-flow model) and $201.00 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $208.78, at 7.8% it would be $265.31.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.4% on the twelve months before. Revenue has grown strongly since 2006, at around 17% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 68%, operating 15%, net 10%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 28 Oct 2026EPS reported $2.80 (expected $2.77)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $11.14−1.1%
- Revenue
- $4.13B−0.6%
- Earnings per share
- $12.30−1.1%
- Revenue
- $4.25B−1.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: +1.2%Align lowered its 2026 revenue guidance to $4.11 to $4.13 billion versus its prior Q2 outlook, due to weaker Systems and Services revenue and lower Clear Aligner volume and pricing assumptions.
“Our updated 2026 guidance reflects a reduction in expected reported revenue versus our prior outlook provided at Q2, driven by 2 main factors. First, our Q4 Systems and Services revenues outlook is lower than our prior guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Morici JohnSale
18 Feb 2026, EVP, CHIEF FINANCIAL OFFICER
- Shares
- 7,969
- Price
- $189.31
- Value
- $1.51M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Align Technology
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Sonova HoldingSOON.SW $20.24B74
- GlaukosGKOS $14.63B48
- Smith & NephewSNN $12.99B67
- PenumbraPEN $12.68B59
- Olympus7733.T $11.7B70
- DemantDEMANT.CO $11.62B73
- InsuletPODD $10.41B65
- Bio-Rad LaboratoriesBIO $10.38B61
ETFs that hold Align Technology
Held by 32 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers S&P 500 Equal Weight UCITS ETF 1CXDEW | 0.22% | 0.15% | €14.88B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.16% | 0.15% | €3.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.16% | 0.43% | €2.48B |
Show 5 more
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.16% | 0.15% | €592.11M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.13% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.10% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.08% | 0.35% | €434.1M |
| Invesco RAFI US Fundamental Value UCITS ETF6PSA | 0.04% | 0.39% | €1.23B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.